A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Public ClinicalTrials.gov record NCT04736706. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, as First-Line Treatment in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.
Study identification
- NCT ID
- NCT04736706
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,688 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- Belzutifan Drug
- Pembrolizumab/Quavonlimab Biological
- Lenvatinib Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2021 (Actual)
- Primary completion
- Feb 4, 2026 (Actual)
- Completion
- Apr 22, 2027 (Estimated)
- Last update posted
- Oct 2, 2026
2021 – 2027
United States locations
- U.S. sites
- 33
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Alabama at Birmingham ( Site 0010) | Birmingham | Alabama | 35294-3300 | — |
| UC San Diego ( Site 0050) | La Jolla | California | 92037 | — |
| Cedars Sinai Medical Center ( Site 0027) | Los Angeles | California | 90048 | — |
| University of California Irvine ( Site 0029) | Orange | California | 92868 | — |
| UCLA Hematology Oncology Santa Monica ( Site 0048) | Santa Monica | California | 90404 | — |
| Hartford Hospital ( Site 0024) | Hartford | Connecticut | 06102 | — |
| Advent Health Hematology & Oncology ( Site 0003) | Orlando | Florida | 32804 | — |
| University Cancer & Blood Center, LLC ( Site 0057) | Athens | Georgia | 30607 | — |
| Emory University Winship Cancer Institute ( Site 0012) | Atlanta | Georgia | 30322 | — |
| Rush University Medical Center ( Site 0040) | Chicago | Illinois | 60607 | — |
| Parkview Cancer Institute ( Site 0088) | Fort Wayne | Indiana | 46845 | — |
| Norton Cancer Institute - St. Matthews ( Site 0065) | Louisville | Kentucky | 40207 | — |
| Ochsner Medical Center ( Site 0049) | New Orleans | Louisiana | 70121 | — |
| New England Cancer Specialists ( Site 0082) | Scarborough | Maine | 04074 | — |
| Massachusetts General Hospital ( Site 0094) | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center ( Site 0089) | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute ( Site 0093) | Boston | Massachusetts | 02215 | — |
| Lahey Hospital & Medical Center ( Site 0090) | Burlington | Massachusetts | 01805 | — |
| Henry Ford Hospital ( Site 0038) | Detroit | Michigan | 48202 | — |
| Cancer & Hematology Centers of Western Michigan ( Site 0018) | Grand Rapids | Michigan | 49503 | — |
| HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0005) | Saint Louis Park | Minnesota | 55426 | — |
| Regions Hospital ( Site 0095) | Saint Paul | Minnesota | 55101 | — |
| University of Mississippi Medical Center ( Site 0037) | Jackson | Mississippi | 39216 | — |
| Dartmouth Hitchcock Medical Center ( Site 0075) | Lebanon | New Hampshire | 03756 | — |
| Roswell Park Cancer Institute ( Site 0032) | Buffalo | New York | 14263 | — |
| R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0013) | Lake Success | New York | 11042 | — |
| Sidney Kimmel Center for Prostate and Urologic Cancers ( Site 0055) | New York | New York | 10065 | — |
| Oregon Health & Science University ( Site 0071) | Portland | Oregon | 97239 | — |
| Ralph H. Johnson VA Center ( Site 0073) | Charleston | South Carolina | 29401 | — |
| University of Tennessee Medical Center Knoxville ( Site 0019) | Knoxville | Tennessee | 37920 | — |
| Vanderbilt University Medical Center ( Site 0069) | Nashville | Tennessee | 37232 | — |
| UTSW Medical Center ( Site 0015) | Dallas | Texas | 75390 | — |
| Central Washington Health Services Association d/b/a Confluence Health ( Site 0061) | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 229 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04736706, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 2, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04736706 live on ClinicalTrials.gov.